2.87

0.00% 0.00

Boundless Bio Inc (BOLD)

Overview News Price History Discussions Forecast

Boundless Bio Inc stock is traded at $2.87, with a volume of 20,000. It is up +0.00% in the last 24 hours and up +6.10% over the past month. Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Previous Close:

$2.87

Open:

$2.87

24h Volume:

20,000

Relative Volume:

0.02

Market Cap:

$65.29M

Revenue:

Net Income/Loss:

$-55.99M

P/E Ratio:

-1.1474

EPS:

-2.5013

Net Cash Flow:

$-47.60M

1W Performance:

+1.41%

1M Performance:

+6.10%

6M Performance:

+151.75%

1Y Performance:

+153.98%

1-Day Range:

$2.86

$2.89

1-Week Range:

$2.80

$2.94

52-Week Range:

$0.9612

$3.1636

Boundless Bio Inc Stock (BOLD) Company Profile

Name

Boundless Bio Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(858) 766-9912

Address

10955 ALEXANDRIA WAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

BOLD's Discussions on Twitter

Compare BOLD vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BOLD Boundless Bio Inc	2.87	65.97M	0	-55.99M	-47.60M	-2.5013
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Initiated	H.C. Wainwright	Buy
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Guggenheim	Buy
Apr-22-24	Initiated	Leerink Partners	Outperform
Apr-22-24	Initiated	Piper Sandler	Overweight

View All

Boundless Bio Inc Stock (BOLD) Latest News

Aug 20, 2026

Boundless (BOLD) Session: Climbs 1.40% to $2.90 in the Current Update; Trading Range: Price Remains Between $2.75 Support and $3.04 Resistance on the DayFactor Timing - vinanet.vn

Aug 20, 2026

Boundless (BOLD) Results Versus Estimates: Profit Per Share Falls Below Its Benchmark in the Available Record; Shares Show Limited Movement under the Current SnapshotFiscal Year Earnings - vinanet.vn

Aug 20, 2026

Aug 14, 2026

Boundless Bio (BOLD): ADAR1 Capital discloses 8.8% beneficial ownership stake - Stock Titan

Aug 14, 2026

Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership - Stock Titan

Aug 14, 2026

Aug 13, 2026

Boundless Bio (BOLD) Edges Up to $2.79 as Stock Holds Tight Trading RangeTriple Bottom - Vinanet

Aug 13, 2026

Aug 07, 2026

Boundless Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026